IIN · Intricon Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.06M | - | $31.05M | $30.21M | $31.77M | - | $27.37M | $23.60M | $21.50M | - |
| Cost of Revenue | $24.19M | - | $23.86M | $22.34M | $23.56M | - | $20.17M | $17.00M | $16.93M | - |
| Gross Profit | $8.87M | - | $7.18M | $7.87M | $8.21M | - | $7.20M | $6.61M | $4.57M | - |
| R&D | $1.59M | - | $1.17M | $1.31M | $1.29M | - | $1.46M | $1.21M | $1.20M | - |
| SG&A | $4.31M | - | $3.94M | $4.07M | $4.05M | - | $3.65M | $4.60M | $3.42M | - |
| Total Operating Expenses | $9.30M | - | $6.71M | $8.81M | $7.36M | - | $6.73M | $9.16M | $6.61M | - |
| D&A | $1.46M | - | - | - | $1.44M | - | $1.26M | $1.13M | $921.0K | - |
| Operating Income | ($429.0K) | - | $478.0K | ($943.0K) | $848.0K | - | $468.0K | ($2.55M) | ($2.04M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $15.0K | - | $8.0K | $80.0K | $90.0K | - | $47.0K | $29.0K | $18.0K | - |
| Net Income | ($657.0K) | - | $337.0K | ($1.18M) | $714.0K | - | $644.0K | ($2.28M) | ($1.98M) | - |
| EPS - Basic | ($0.07) | - | $0.04 | ($0.13) | $0.08 | - | $0.07 | ($0.26) | ($0.22) | - |
| EPS - Diluted | ($0.07) | - | $0.04 | ($0.13) | $0.07 | - | $0.07 | ($0.26) | ($0.22) | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.31M | $5.58M | $13.02M | $6.08M | $11.76M | $8.61M | $16.08M | $7.06M | $15.18M | - |
| Accounts Receivable | $11.09M | $8.26M | $9.68M | $9.59M | $9.45M | $10.12M | $9.19M | $10.45M | $8.24M | $8.99M |
| Inventory | $28.44M | $24.46M | $22.23M | $22.19M | $20.34M | $19.51M | $20.46M | $21.03M | $19.11M | $16.38M |
| Accounts Payable | $13.32M | $9.40M | $10.32M | $10.10M | $12.13M | $8.67M | $8.34M | $9.47M | $10.39M | $9.88M |
| Current Assets | $76.62M | $74.38M | $79.26M | $75.03M | $76.64M | $69.27M | $72.58M | $68.78M | $71.54M | $70.28M |
| Total Assets | $126.51M | $122.46M | $123.41M | $124.09M | $125.25M | $121.30M | $116.47M | $116.05M | $111.72M | $113.59M |
| Current Liabilities | $23.95M | $20.21M | $21.52M | $22.63M | $22.46M | $18.66M | $18.59M | $19.44M | $17.30M | $16.93M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $32.74M | $28.71M | $30.54M | $32.13M | $33.01M | $30.10M | $26.97M | $27.62M | $22.94M | $23.10M |
| Stockholders' Equity | $93.61M | $93.66M | $92.78M | $91.89M | $92.30M | $91.16M | $89.47M | $88.68M | $89.03M | $90.75M |
| Retained Earnings | ($7.57M) | ($6.92M) | ($6.94M) | ($7.28M) | ($6.10M) | ($6.81M) | ($7.90M) | ($8.55M) | ($6.26M) | ($4.29M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.66M) | - | - | - | $5.87M | - | - | - | ($1.24M) | - |
| Investing Cash Flow | $1.63M | - | - | - | ($2.51M) | - | - | - | $8.01M | - |
| Financing Cash Flow | ($311.0K) | - | - | - | ($245.0K) | - | - | - | ($158.0K) | - |
| CapEx | $2.00M | - | - | - | $851.0K | - | $610.0K | $274.0K | $1.68M | - |
| Free Cash Flow | ($3.66M) | - | - | - | $5.01M | - | - | - | ($2.91M) | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 26.8% | - | 23.1% | 26.1% | 25.8% | - | 26.3% | 28.0% | 21.3% | - |
| Operating margin | -1.3% | - | 1.5% | -3.1% | 2.7% | - | 1.7% | -10.8% | -9.5% | - |
| EBITDA margin | 3.1% | - | - | - | 7.2% | - | 6.3% | -6.0% | -5.2% | - |
| Net margin | -2.0% | - | 1.1% | -3.9% | 2.2% | - | 2.4% | -9.7% | -9.2% | - |
| Free cash flow margin | -11.1% | - | - | - | 15.8% | - | - | - | -13.6% | - |
| FCF / Net income | 5.57 | - | - | - | 7.02 | - | - | - | 1.47 | - |
| R&D / Revenue | 4.8% | - | 3.8% | 4.3% | 4.1% | - | 5.3% | 5.1% | 5.6% | - |
| SG&A / Revenue | 13.0% | - | 12.7% | 13.5% | 12.8% | - | 13.4% | 19.5% | 15.9% | - |
| Effective tax rate | - | - | 2.3% | - | 11.2% | - | 6.8% | - | - | - |
| Return on assets | -0.5% | - | 0.3% | -1.0% | 0.6% | - | 0.6% | -2.0% | -1.8% | - |
| Return on equity | -0.7% | - | 0.4% | -1.3% | 0.8% | - | 0.7% | -2.6% | -2.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.20 | 3.68 | 3.68 | 3.31 | 3.41 | 3.71 | 3.90 | 3.54 | 4.14 | 4.15 |
| Quick ratio | 2.01 | 2.47 | 2.65 | 2.33 | 2.51 | 2.67 | 2.80 | 2.46 | 3.03 | 3.18 |
| Cash ratio | 0.22 | 0.28 | 0.61 | 0.27 | 0.52 | 0.46 | 0.87 | 0.36 | 0.88 | - |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.35 | 1.31 | 1.33 | 1.35 | 1.36 | 1.33 | 1.30 | 1.31 | 1.25 | 1.25 |
| Liabilities / Assets | 0.26 | 0.23 | 0.25 | 0.26 | 0.26 | 0.25 | 0.23 | 0.24 | 0.21 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | 0.26 | - | 0.25 | 0.24 | 0.25 | - | 0.23 | 0.20 | 0.19 | - |
| Inventory turnover | 0.85 | - | 1.07 | 1.01 | 1.16 | - | 0.99 | 0.81 | 0.89 | - |
| Days sales outstanding | 122d | - | 114d | 116d | 109d | - | 123d | 162d | 140d | - |
| Days inventory outstanding | 429d | - | 340d | 362d | 315d | - | 370d | 452d | 412d | - |
| Days payable outstanding | 201d | - | 158d | 165d | 188d | - | 151d | 203d | 224d | - |
| Cash conversion cycle | 351d | - | 296d | 313d | 236d | - | 342d | 410d | 328d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 4.1% | - | 13.5% | 28.0% | 47.7% | - | 1.8% | -19.5% | -28.6% | - |
| Revenue CAGR (3y) | 3.2% | - | 7.4% | 10.3% | 14.4% | - | 20.7% | 2.4% | 6.0% | - |
| Revenue CAGR (5y) | 12.8% | - | 12.4% | 12.0% | 13.9% | - | 10.0% | 6.2% | 4.4% | - |
| Gross profit growth (YoY) | 8.1% | - | -0.2% | 19.2% | 79.6% | - | 6.3% | -19.6% | -47.8% | - |
| Operating income growth (YoY) | - | - | 2.1% | 63.0% | - | - | - | 24.3% | - | - |
| Net income growth (YoY) | - | - | -47.7% | 48.3% | - | - | - | 54.7% | - | - |
| EPS growth (YoY) | - | - | -42.9% | 50.0% | - | - | - | 54.4% | - | - |
| EPS CAGR (3y) | - | - | -43.3% | - | -11.2% | - | -22.4% | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | -6.9% | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -461.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 1.4% | 2.7% | 3.7% | 3.6% | 3.7% | 0.5% | -0.1% | -0.6% | -4.6% | -1.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$119.85M totalDiabetes$69.73M · 58.2%
Interventional Catheters$14.57M · 12.2%
Hearing Health Legacy Oem$10.85M · 9.1%
Medical Biotelemetry Other$8.72M · 7.3%
Hearing Health Value Based ITEC$8.05M · 6.7%
Professional Audio Communications$4.44M · 3.7%
Hearing Health Value Based DTEC$3.48M · 2.9%
Geographic
$125.21M totalUS$92.92M · 74.2%
All Other Countries$13.17M · 10.5%
Asia$12.55M · 10.0%
Europe$6.56M · 5.2%
Peer comparison
Same SIC group: Electronic Components & Accessories
Comparing INTRICON CORP against the 5 most active filers in the same SIC group.